Background: There are a limited number of studies investigating the side effects and effectiveness of various doses of isotretinoin (ISO). We have previously shown that high-dose ISO affects pituitary hormones. Objectives: To our knowledge, there is no study in the literature looking into the effects of various doses of ISO on pituitary hormones. We searched pituitary hormones in three groups of different doses in acne patients. Methods: We included 105 acne vulgaris patients from two different centers. We divided the patients into three groups; the first group received 0.5-1 mg/kg/day, the second 0.2-0.5 mg/kg/day and the third intermittent 0.5-1 mg/kg/day (only 1 week in 1 month) ISO treatment. Blood samples were collected for biochemistry and hormone analysis, before the treatment and after 3 months. Results: After 3 months of treatment with ISO, luteinizing hormone (LH) (p < 0.001), prolactin (p < 0.001), total testosterone (p < 0.001), adrenocorticotropic hormone (ACTH) (p < 0.001), cortisol (p < 0.001), insulin-like growth factor-binding protein 3 (p < 0.001), insulin-like growth factor 1 (IGF-1) (p = 0.002), growth hormone (GH) (p = 0.002) and free T3 (fT3) (p < 0.001) levels had decreased significantly. Furthermore, we split data into three different groups. Among the patients receiving intermittent-dose ISO, LH, ACTH, IGF-1, GH and fT3 measurements lost significance. Most of the significant measurements observed in the whole group were also significant among the patients receiving high-dose ISO. Additionally, dehydroepiandrosterone sulfate (p = 0.003) levels increased, and free T4 levels decreased significantly. Conclusions: ISO affects pituitary hormones at all of these three doses. The differences in pituitary hormones are more pronounced in high-dose treatment. The weakest effect was observed in the intermittent-dose group. Choosing lower doses of ISO may decrease side effects, however the effectiveness of the treatment may also be diminished. ISO, by affecting the PPARγ/RXR system, may affecting hormone systems. These changes in various hormone systems may be related to the effectiveness of ISO.

Keywords:
Isotretinoin, Pituitary hormones
1.
Layton A: The use of isotretinoin in acne. Dermatoendocrinol 2009;1:162-169.
2.
Lolis MS, Bowe WP, Shalita AR: Acne and systemic disease. Med Clin North Am 2009;93:1161-1181.
3.
Karadag AS, Ertugrul DT, Tutal E, Akin KO: Isotretinoin influences pituitary hormone levels in acne patients. Acta Derm Venereol 2011;91:31-34.
4.
Goulden V, Clark SM, McGeown C, Cunliffe WJ: Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997;137:106-108.
5.
Hermes B, Praetel C, Henz BM: Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol 1998;11:117-121.
6.
Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G: Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 2003;23:41-46.
7.
Amichai B, Shemer A, Grunwald MH: Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:644-646.
8.
Kaymak Y, Ilter N: The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol 2006;20:1256-1260.
9.
Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E: Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 2007;299:467-473.
10.
Sardana K, Garg VK: Low-dose isotretinoin in acne vulgaris: a critical review. Br J Dermatol 2011;165:698-700.
11.
Stewart ME, Benoit AM, Stranieri AM, Rapini RP, Strauss JS, Downing DT: Effect of oral 13-cis-retinoic acid at three dose levels on sustainable rates of sebum secretion and on acne. J Am Acad Dermatol 1983;8:532-538.
12.
Lee JW, Yoo KH, Park KY, Han TY, Li K, Seo SJ, Hong CK: Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011;164:1369-1375.
13.
Masood MQ, Hakeem H: Isotretinoin associated reversible hypothyroidism. Thyroid 2011;21:1039-1040.
14.
Heliövaara MK, Remitz A, Reitamo S, Teppo AM, Karonen SL, Ebeling P: 13-cis-retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 2007;56:786-791.
15.
Inamo Y, Suzuki T, Mugishima H: A case of growth failure caused by 13-CIS-retinoic acid administration after bone marrow transplantation for neuroblastoma. Endocr J 1999;46 (suppl):S113-S115.
16.
Karadag AS, Ertugrul DT, Tutal E, Akin KO: Short term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: does isotretinoin affect growth hormone physiology? Br J Dermatol 2010;162:798-802.
17.
Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W: FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009;23:213-225.
18.
Yanase T, Fan W: Modification of androgen receptor function by IGF-1 signaling: implications in the mechanism of refractory prostate carcinoma. Vitam Horm 2009;80:649-666.
19.
Arora MK, Yadav A, Saini V: Role of hormones in acne vulgaris. Clin Biochem 2011;44:1035-1040.
20.
Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H: Glucocorticoids enhance Toll-like receptor-2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol 2009;129:375-382.
21.
Deplewski D, Rosenfield RL: Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology 1999;140:4089-4094.
22.
Karadag AS, Kalkan G, Lin YT, Chen W: Update of oral isotretinoin in acne treatment; in Khanna N, Kubba R (eds): World Clinics: Dermatology - Acne. New Delhi, Jaypee Brothers, 2013, pp 169-200.
23.
Melnik BC: Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol 2011;3:141-165.
24.
Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB: The transcription of FOXO genesis stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009;284:10334-10342.
25.
Melnik BC: FoxO1 - the key for the pathogenesis and therapy of acne? J Dtsch Dermatol Ges 2010;8:105-114.
26.
Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF: Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008;8:65-76.
27.
Yang G, Lim CY, Li C, Xiao X, Radda GK, Li C, Cao X, Han W: FoxO1 inhibits leptin regulation of pro-opiomelanocortin promoter activity by blocking STAT3 interaction with specificity protein 1. J Biol Chem 2009;284:3719-3727.
28.
Melnik BC, Schmitz G: Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol 2009;18:833-841.
29.
Smith TM, Gilliland K, Clawson GA, Thiboutot D: IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008;128:1286-1293.
30.
Cappel M, Mauger D, Thiboutot D: Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 2005;141:333-338.
31.
Edmondson SR, Thumiger SP, Werther GA, Wraight CJ: Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr Rev 2003;24:737-764.
32.
Marsden JR, Trinick TR, Laker MF, Shuster S: Effects of isotretinoin on serum lipids and lipoproteins, liver and thyroid function. Clin Chim Acta 1984;143:243-251.
33.
Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M: Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-1079.
34.
Lyons F, Laker MF, Marsden JR, Manuel R, Shuster S: Effect of oral 13-cis-retinoic acid on serum lipids. Br J Dermatol 1982;107:591-595.
35.
Agarwal US, Besarwal RK, Bhola K: Oral isotretinoin in different dose regimens for acne vulgaris: a randomized comparative trial. Indian J Dermatol Venereol Leprol 2011;77:688-694.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.